Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human

Abstract 1. New insight into the in vitro and in vivo metabolism of Cladribine (2-chloro-2′-deoxyadenosine, [2-CdA]) are presented. 2. Following incubation of [14C]-2-CdA in mouse, rat, rabbit, dog, monkey and human hepatocyte cultures, variable turnover was observed with oxidations and direct glucuronidation pathways. The oxidative cleavage to 2-chloroadenine (2-CA, M1) was only observed in rabbit and rat. 3. Following incubation of [14C]-2-CdA in whole blood from mouse, monkey and human, a significant turnover was observed. The main metabolites in monkey and human were 2-chlorodeoxyinosine (M11, 16% of total radioactivity) and 2-chlorodeoxyinosine (M12, 43%). In mouse, 2-CA was the major metabolite (2-CA; M1, 73%). 4. After single intravenous and oral administration of [14C]-2-CdA to mice, 2-chlorodeoxyinosine (M11) was confirmed in plasma, while 2-chlorohypoxanthine (M12) and 2-CA (M1) were found in urine. 5. Overall, the use of [14C]-2-CdA both in vitro (incubations in mouse, monkey and human whole blood) and in vivo (mouse) has confirmed the existence of an additional metabolism pathway leading to the formation of 2-chlorodeoxyinosine (M11) and 2-chlorohypoxanthine (M12). Formation of these two metabolites demonstrates that Cladribine as free form is not fully resistant to adenosine deaminase as suggested earlier, an enzyme involved in its mode of action.

[1]  T. Leist,et al.  Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis , 2011, Clinical neuropharmacology.

[2]  P. Vermersch,et al.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[3]  A. Rohatiner,et al.  Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.

[4]  P. Bonate,et al.  THE DISTRIBUTION, METABOLISM, AND ELIMINATION OF CLOFARABINE IN RATS , 2005, Drug Metabolism and Disposition.

[5]  A. Saven,et al.  Cladribine: from the bench to the bedside – focus on hairy cell leukemia , 2004, Expert review of anticancer therapy.

[6]  G. Juliusson,et al.  Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. , 2004, Cancer letters.

[7]  H. Caron,et al.  Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  W. Wu,et al.  Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin®) in animals and humans , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  A. Saven.  Treatment of hairy-cell leukemia. , 2001, The New England journal of medicine.

[10]  F. Bontemps,et al.  Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2'-deoxyadenosine. , 2000, Biochemical pharmacology.

[11]  M Filippi,et al.  Cladribine and progressive MS , 2000, Neurology.

[12]  E. Bojarska,et al.  Electrooxidation of the antileukemic 2-chloro-2′-deoxyadenosine and related compounds , 1999 .

[13]  J. Koziol,et al.  Cladribine in treatment of chronic progressive multiple sclerosis , 1994, The Lancet.

[14]  J. Koziol,et al.  Marrow suppression produced by repeated doses of cladribine. , 1994, Acta haematologica.

[15]  E. Beutler.  Cladribine (2-chlorodeoxyadenosine) , 1992, The Lancet.

[16]  T. Kipps,et al.  Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Fitchen,et al.  Purine metabolism as a target for leukemia chemotherapy. , 1989, Blood reviews.

[18]  D. Carson,et al.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. , 1985, The Journal of clinical investigation.

[19]  D. Carson,et al.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[20]  U. Al-Khalidi,et al.  The species distribution of xanthine oxidase. , 1965, The Biochemical journal.

[21]  A. Saven,et al.  2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside. , 1991, Leukemia & lymphoma.

[22]  A. Yu,et al.  Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. , 1983, Blood.